R. Asola

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono et al. · New England Journal of Medicine · 2006 · 1.4K citations

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

Heikki Joensuu, Petri Bono, Vesa Kataja et al. · Journal of Clinical Oncology · 2009 · 458 citations · Full text

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

Pirkko‐Liisa Kellokumpu‐Lehtinen, Ulrika Harmenberg, Timo Joensuu et al. · The Lancet Oncology · 2013 · 205 citations

Urology, Oncology, Genitourinary Cancer +5

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen et al. · Journal of Clinical Oncology · 2011 · 116 citations · Full text

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen et al. · The Lancet Oncology · 2009 · 63 citations

Breast Oncology, Oncology, Medicine +7